Literature DB >> 32601975

The role of fibroblast activation protein in health and malignancy.

Allison A Fitzgerald1, Louis M Weiner2.   

Abstract

Fibroblast activation protein-α (FAP) is a type-II transmembrane serine protease expressed almost exclusively to pathological conditions including fibrosis, arthritis, and cancer. Across most cancer types, elevated FAP is associated with worse clinical outcomes. Despite the clear association between FAP and disease severity, the biological reasons underlying these clinical observations remain unclear. Here we review basic FAP biology and FAP's role in non-oncologic and oncologic disease. We further explore how FAP may worsen clinical outcomes via its effects on extracellular matrix remodeling, intracellular signaling regulation, angiogenesis, epithelial-to-mesenchymal transition, and immunosuppression. Lastly, we discuss the potential to exploit FAP biology to improve clinical outcomes.

Entities:  

Keywords:  Fibroblast activation protein (FAP); Fibroblasts; Invasion; Stroma

Mesh:

Substances:

Year:  2020        PMID: 32601975      PMCID: PMC7487063          DOI: 10.1007/s10555-020-09909-3

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  113 in total

1.  Cleavage-site specificity of prolyl endopeptidase FAP investigated with a full-length protein substrate.

Authors:  Chih-Hsiang Huang; Ching-Shu Suen; Ching-Ting Lin; Chia-Hui Chien; Hsin-Ying Lee; Kuei-Min Chung; Ting-Yueh Tsai; Weir-Tong Jiaang; Ming-Jing Hwang; Xin Chen
Journal:  J Biochem       Date:  2011-02-01       Impact factor: 3.387

2.  The expression of a type II transmembrane serine protease (Seprase) in human gastric carcinoma.

Authors:  Yoshiyuki Mori; Koji Kono; Yoshirou Matsumoto; Hideki Fujii; Tetsu Yamane; Masako Mitsumata; Wen-Tien Chen
Journal:  Oncology       Date:  2004       Impact factor: 2.935

3.  Identification of the 170-kDa melanoma membrane-bound gelatinase (seprase) as a serine integral membrane protease.

Authors:  M L Piñeiro-Sánchez; L A Goldstein; J Dodt; L Howard; Y Yeh; H Tran; W S Argraves; W T Chen
Journal:  J Biol Chem       Date:  1997-03-21       Impact factor: 5.157

4.  Antiplasmin-cleaving enzyme is a soluble form of fibroblast activation protein.

Authors:  Kyung N Lee; Kenneth W Jackson; Victoria J Christiansen; Chung S Lee; Jin-Geun Chun; Patrick A McKee
Journal:  Blood       Date:  2005-10-13       Impact factor: 22.113

5.  Tumoral immune suppression by macrophages expressing fibroblast activation protein-α and heme oxygenase-1.

Authors:  James N Arnold; Lukasz Magiera; Matthew Kraman; Douglas T Fearon
Journal:  Cancer Immunol Res       Date:  2013-11-18       Impact factor: 11.151

6.  Purification, identification and characterisation of seprase from bovine serum.

Authors:  Patrick J Collins; Gillian McMahon; Pamela O'Brien; Brendan O'Connor
Journal:  Int J Biochem Cell Biol       Date:  2004-11       Impact factor: 5.085

7.  Peptide substrate profiling defines fibroblast activation protein as an endopeptidase of strict Gly(2)-Pro(1)-cleaving specificity.

Authors:  Conrad Yap Edosada; Clifford Quan; Thuy Tran; Victoria Pham; Christian Wiesmann; Wayne Fairbrother; Beni B Wolf
Journal:  FEBS Lett       Date:  2006-02-03       Impact factor: 4.124

8.  Fibroblast activation protein peptide substrates identified from human collagen I derived gelatin cleavage sites.

Authors:  Saurabh Aggarwal; W Nathaniel Brennen; Thomas P Kole; Elizabeth Schneider; Ozlem Topaloglu; Melinda Yates; Robert J Cotter; Samuel R Denmeade
Journal:  Biochemistry       Date:  2007-12-21       Impact factor: 3.162

9.  A potential marker protease of invasiveness, seprase, is localized on invadopodia of human malignant melanoma cells.

Authors:  W L Monsky; C Y Lin; A Aoyama; T Kelly; S K Akiyama; S C Mueller; W T Chen
Journal:  Cancer Res       Date:  1994-11-01       Impact factor: 12.701

10.  Seprase, a membrane-bound protease, is overexpressed by invasive ductal carcinoma cells of human breast cancers.

Authors:  T Kelly; S Kechelava; T L Rozypal; K W West; S Korourian
Journal:  Mod Pathol       Date:  1998-09       Impact factor: 7.842

View more
  29 in total

1.  Radiotracers to Address Unmet Clinical Needs in Cardiovascular Imaging, Part 2: Inflammation, Fibrosis, Thrombosis, Calcification, and Amyloidosis Imaging.

Authors:  John C Stendahl; Jennifer M Kwan; Darko Pucar; Mehran M Sadeghi
Journal:  J Nucl Med       Date:  2022-07       Impact factor: 11.082

2.  Distinguishing Benign and Malignant Findings on [68 Ga]-FAPI PET/CT Based on Quantitative SUV Measurements.

Authors:  M Dabir; E Novruzov; K Mattes-György; M Beu; K Dendl; C Antke; S A Koerber; M Röhrich; C Kratochwil; J Debus; U Haberkorn; F L Giesel
Journal:  Mol Imaging Biol       Date:  2022-08-23       Impact factor: 3.484

3.  Fibroblast activation protein in the tumor microenvironment predicts outcomes of PD-1 blockade therapy in advanced non-small cell lung cancer.

Authors:  Yan Zhao; Yueping Liu; Yunlong Jia; Xiaoxiao Wang; Jiankun He; Shuman Zhen; Jiali Wang; Lihua Liu
Journal:  J Cancer Res Clin Oncol       Date:  2022-08-11       Impact factor: 4.322

4.  Preclinical evaluation and pilot clinical study of [18F]AlF-NOTA-FAPI-04 for PET imaging of rheumatoid arthritis.

Authors:  Luna Ge; Zheng Fu; Yuchun Wei; Dandan Shi; Yun Geng; Huancai Fan; Ruojia Zhang; Yuang Zhang; Shufeng Li; Shijie Wang; Haojun Shi; Guanhua Song; Jihong Pan; Kai Cheng; Lin Wang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-06-18       Impact factor: 10.057

Review 5.  ImmunoPET: Antibody-Based PET Imaging in Solid Tumors.

Authors:  Reyhaneh Manafi-Farid; Bahar Ataeinia; Shaghayegh Ranjbar; Zahra Jamshidi Araghi; Mohammad Mobin Moradi; Christian Pirich; Mohsen Beheshti
Journal:  Front Med (Lausanne)       Date:  2022-06-28

6.  Correlation of 68Ga-FAPi-46 PET Biodistribution with FAP Expression by Immunohistochemistry in Patients with Solid Cancers: Interim Analysis of a Prospective Translational Exploratory Study.

Authors:  Christine E Mona; Matthias R Benz; Firas Hikmat; Tristan R Grogan; Katharina Lueckerath; Aria Razmaria; Rana Riahi; Roger Slavik; Mark D Girgis; Giuseppe Carlucci; Kimberly A Kelly; Samuel W French; Johannes Czernin; David W Dawson; Jeremie Calais
Journal:  J Nucl Med       Date:  2021-11-05       Impact factor: 11.082

Review 7.  Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer.

Authors:  Fanglong Wu; Jin Yang; Junjiang Liu; Ye Wang; Jingtian Mu; Qingxiang Zeng; Shuzhi Deng; Hongmei Zhou
Journal:  Signal Transduct Target Ther       Date:  2021-06-10

Review 8.  The Role of p53 Dysfunction in Colorectal Cancer and Its Implication for Therapy.

Authors:  Maurice Michel; Leonard Kaps; Annett Maderer; Peter R Galle; Markus Moehler
Journal:  Cancers (Basel)       Date:  2021-05-11       Impact factor: 6.639

Review 9.  Oncogenesis, Microenvironment Modulation and Clinical Potentiality of FAP in Glioblastoma: Lessons Learned from Other Solid Tumors.

Authors:  Yixin Shi; Ziren Kong; Penghao Liu; Guozhu Hou; Jiaming Wu; Wenbin Ma; Xin Cheng; Yu Wang
Journal:  Cells       Date:  2021-05-10       Impact factor: 6.600

Review 10.  Immune Cells and Immunotherapy for Cardiac Injury and Repair.

Authors:  Joel G Rurik; Haig Aghajanian; Jonathan A Epstein
Journal:  Circ Res       Date:  2021-05-27       Impact factor: 23.213

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.